Boosted-PI–Based ART vs. Triple NRTIs for HIV-2 Infection

In a study involving 170 HIV-2–infected patients, boosted protease inhibitor–based ART was more effective than triple nucleoside reverse transcriptase inhibitor therapy.

Data on treatment of HIV-2 infection remain limited. Available nonnucleoside reverse transcriptase inhibitors are not active against HIV-2, so options for antiretroviral therapy (ART) have generally been confined to triple nucleoside reverse transcriptase inhibitor (NRTI) or boosted protease inhibitor (PI)–based regimens. The WHO currently suggests initial use of triple-NRTI ART for HIV-2 infection, whereas the U.S. Department of Health and Human Services guidelines recommend starting with boosted-PI–based therapy.

In a retrospective, partially industry-funded study, investigators assessed immunological and virological responses in 170 treatment-naive HIV-2–monoinfected patients from seven European cohorts. Forty-four of the patients receive…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Boosted-PI–Based ART vs. Triple NRTIs for HIV-2 Infection

Topics

Reviewing Author